Louisiana Clinical Trials

A listing of Louisiana clinical trials actively recruiting patient volunteers.

Filter by Condition
955 trials found

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.

Conditions: Squamous Cell Carcinoma of the Head and Neck

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

NCT04583514

Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the ...

Conditions: Overweight and Obesity, Metabolic Syndrome
Phase: Not Applicable

Big Effect Trial (BET-A) for the Treatment of COVID-19

NCT04583956

This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with COVID-19. BET is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 40 sites throughout the US. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively la ...

Conditions: COVID-19

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949

This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as repeating that duration for a total of 84 days/12 weeks treatment.

Conditions: Smoking Cessation

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

NCT04560998

This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for ...

Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT04556383

A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of 2 dose regimens of GB004 in adult subjects with mild-to-moderate active UC and who have disease activity despite treatment with 5-aminosalicylate (5-ASA). The primary objective of this study is to evaluate the effect of GB004 compared to placebo on clinical remission.

Conditions: Ulcerative Colitis

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267

The primary objective of the study is to compare the clinical efficacy of high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in participants 6 months through 35 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B type. The secondary objectives of the study are: To compare QIV-HD to QIV-SD: in participants 6 months through 35 months of age for the prevention of laboratory-confirmed infl ...

Conditions: Influenza

Single vs. Dual-DCCV in Obese Patients

NCT04539158

Currently, the usual initial strategy for direct current cardioversion (DCCV) typically involves delivering 200J of electricity between two pads placed in the anterior and posterior positions (i.e., one on the chest and one on the back). However, this technique may be less likely to result in successful cardioversion in obese patients (BMI ≥30 kg/m2). Failure to achieve sinus rhythm then necessitates additional shocks, which still may ultimately fail to terminate the patient's atrial fibrillatio ...

Conditions: Atrial Fibrillation
Phase: Not Applicable

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

NCT04538066

To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).

Conditions: Alzheimer Disease

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study

NCT04535531

This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.

Conditions: Molluscum Contagiosum

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

NCT04530955

Comparing the efficacy of Intracthecal Baclofen dose between the Prometra II and Medtronic SynchroMed II for patients with spasticity and with current a current SyncroMed II pump needing replacement.

Conditions: Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Phase: Not Applicable

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults Aged 18 to 49 Years and in Children Aged 12 to 36 Months Who Are Respiratory Syncytial Virus Seropositive

NCT04528719

The primary objectives of this study are to evaluate the tolerability and reactogenicity of a single injection of 1 of 3 dose levels of mRNA-1345 in adults, of 3 injections of the middle dose level of mRNA-1345 given 56 days apart in adults, and of 3 injections of 1 of 2 dose levels of mRNA-1345 given 56 days apart in children who are RSV-seropositive.

Conditions: Respiratory Syncytial Virus